Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Iterum Therapeutics plc (ITRM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest expense, net Adjustments to fair value of derivatives 2,155 7,332 Other income, net 50 269 91 431 Income tax expense Net loss $ $ $ $ Net loss per share – basic and diluted $ $ $ $ Weighted average ordinary shares outstanding – basic and diluted 12,942,969 12,224,324 12,812,398 12,208,961 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ $ $ Intangible asset amortization 429 429 858 858 Share based compensation 110 1,984 503 3,879 Interest expense - accrued interest and amortization on Exchang..."
08/01/2023 8-K Quarterly results
07/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/12/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations Three Months Ended March 31, 2023 2022 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest expense, net Adjustments to fair value of derivatives 5,177 Other income, net 41 162 Income tax expense Net loss $ $ Net loss per share – basic and diluted $ $ Weighted average ordinary shares outstanding – basic and diluted 12,681,900 12,193,435 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ Intangible asset amortization 429 429 Share based compensation 393 1,895 Interest expense - accrued interest and amortization on Exchangeable Notes 783 783 Adjustments to fair value of derivatives 878 Non-GAAP net loss $ $ Net loss per share ..."
05/04/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Iterum Therapeutics public limited company. 2. The Company is a public limited company for the purposes of Part 17 of the Companies Act 2014. 3. The objects for which the Company is established are: a. To carry on the business of a holding company and to coordinate the administration, finances and activities of any subsidiary companies or associated companies, to do all lawful acts and things whatsoever that are necessary or convenient in carrying on the business of such a holding company and in particular to carry on, in all..."
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/16/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/16/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations For the three months ended December 31, Year ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest income / , net 80 Adjustments to fair value of derivatives 2,960 3,562 5,458 Cancellation of share options - - - Other income, net 28 503 195 Income tax expense Net loss attributable to ordinary shareholders $ $ $ $ Net loss per share attributable to ordinary shareholders – basic and diluted $ $ $ $ Weighted average ordinary shares outstanding – basic and diluted 12,294,865 12,185,019 12,236,607 10,891,178 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ $ $ Intangible asset amortiza..."
03/06/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
12/15/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Investor Contact:"
10/20/2022 8-K Quarterly results
10/18/2022 EFFECT Form EFFECT - Notice of Effectiveness:
10/07/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
09/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
08/18/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Iterum Therapeutics public limited company. 2. The Company is a public limited company for the purposes of Part 17 of the Companies Act 2014. 3. The objects for which the Company is established are: 3.1. To carry on the business of a holding company and to coordinate the administration, finances and activities of any subsidiary companies or associated companies, to do all lawful acts and things whatsoever that are necessary or convenient in carrying on the business of such a holding company and in particular to carry on, in a..."
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 8-K Quarterly results
Docs: "Investor Contact:"
07/28/2022 8-K Quarterly results
07/11/2022 8-K Quarterly results
07/08/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/01/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/13/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy